Related Experiment Video
Updated: May 3, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Tumor evolution in response to chemotherapy: phenotype versus genotype
1Department of Genetics, MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Bioinformatics and Computational Biology, MD Anderson Cancer Center, Houston, TX 77030, USA.
This study reveals that cellular phenotypes, not just genetics, drive therapy resistance in breast cancer. These findings challenge previous ideas about genetic bottlenecks during treatment.
Area of Science:
- Oncology
- Genetics
- Cell Biology
Background:
- Intratumor heterogeneity is a key challenge in cancer therapy.
- Understanding treatment resistance mechanisms is crucial for improving patient outcomes.
Purpose of the Study:
- To comprehensively investigate the intratumor heterogeneity of cell phenotypes and genotypes in breast cancer before and after chemotherapy.
- To explore the role of cellular phenotypes and genotypes in the development of therapy resistance.
Main Methods:
- Analysis of breast cancer cell populations before and after chemotherapy.
- Assessment of both phenotypic and genotypic characteristics within tumors.
Main Results:
- Demonstrated significant intratumor heterogeneity in cell phenotypes and genotypes.
- Challenged the traditional concept of genetic population bottlenecks during chemotherapy.
- Highlighted the critical role of cellular phenotypes in mediating resistance to breast cancer therapy.
Conclusions:
- Cellular phenotypes are significant drivers of therapy resistance in breast cancer.
- Future therapeutic strategies should consider phenotypic plasticity alongside genetic profiles.
More Related Videos
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
08:52Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
Related Concept Videos
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Tumor Progression
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer